Biotechnology Jobs & Careers Search

Find your next job in Biotechnology. Search Biotechnology jobs from thousands of job and career search sites. A search engine for jobs with a different approach to job and career searches. In one simple search, job seekers get free access to millions of employment opportunities from thousands of websites. Find your next job in Biotechnology today.

Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide
As global temperatures and energy costs continue to soar, renewable sources of energy will be key to a sustainable future. An attractive replacement for gasoline is biofuel, and in two studies ...

Novartis receives regulatory approval in Germany for cell culture-based Influenza A(H1N1) pandemic vaccine
Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura®. Novartis continues to ...

Catalent expands capabilities in testing for melamine in food and medicinal products
At a time when melamine-contamination has received global attention, Catalent Pharma Solutions continues to rapidly develope new FDA guidance-compliant tests for trace amounts of key contaminants in ...

Hybrid molecules show promise for exploring, treating Alzheimer's
One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the ...

Monsanto Breaks Ground on Lubbock Cotton Research Facility
To increase yield potential and produce better quality fiber are the goals of Monsanto Company's $10.5 million research "megasite" in Lubbock, where the company broke ground on the site. The megasite ...

Study points to new uses, unexpected side effects of already existing drugs
Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new ...

Singapore scientists join international study of 10,000 vertebrates' genomes
The Singapore laboratory that deciphered the DNA codes, or genomes, of the famed fugu (or pufferfish) and elephant shark, has joined The Genome 10K Project, an international effort to build an ...

Magnetic nanoparticles to simultaneously diagnose, monitor and treat
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve ...

Quintiles Opens Expanded Asia-Pacific Headquarters in Singapore
To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and ...

TranScrip Partners appoints David Oxlade as Chairman of the Board
TranScrip Partners LLP, a pharmaceutical development company providing expert advice and hands-on support to pharmaceutical and biotechnology companies across a wide range of therapeutic areas, ...

Deinove receives €6 million in funding from the French state innovation agency OSEO
Deinove, a biotech start-up dedicated to the research and development of processes for biofuel production, announced that it has been awarded €6 million in funding by the French state innovation ...

New Merck begins operations
Merck & Co., Inc. outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, ...

Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry ...

Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Transgene S.A. announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical trials. Transgene is developing TG4023, a Modified Vaccinia ...

Cipher appoints Dr. William Claypool to Board of Directors
Cipher Pharmaceuticals Inc. (announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors.Since October 2008, Dr. Claypool has been a Senior Partner at Pennmark Associates, ...

Drought-tolerant cowpea can improve crop yield in arid West Africa
Even the highly drought-resistant cowpea (a long type of legume) now has an increasingly difficult time surviving in the Sahel countries where climate change has resulted in shorter and less frequent ...

VisualSonics Appoints New President and CEO
VisualSonics Inc. announced that the Board of Directors has permanently appointed Anil Amlani, as President and Chief Executive Officer of the Company. Mr. Amlani, previously the Chief Financial ...

Monsanto Opens First Biotechnology Research Center in China
Monsanto Company announced that it is opening its first research center in China, further demonstrating its commitment to forming technology collaborations in the country. The Monsanto Biotechnology ...

World's largest malaria vaccine trial now underway in 7 African countries
A pivotal efficacy trial of RTS,S, a clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The ...

Flemish researchers develop revolutionary technology for use in plant breeding
In collaboration with researchers at VIB-UGent and The University of Antwerp (UA), scientists at the BioScience business group of Bayer CropScience AG in Gent have developed a technology that can ...

How Drug Advertising Restrictions Could Benefit the Industry
BNET -- The drug business spends $5 billion a year on advertising and yet studies continue to emerge suggesting that hundreds of millions of those dollars are wasted. Perhaps its time to consider whether more restrictions on drug ads might, counterintutively, benefit the industry.

Abraxis BioScience, Inc. Opens $70 Million Phoenix Manufacturing Site; Will Create up to 200 Technology Jobs

IMS Health to be Sold for $5.2 Billion, Employs 1,000 in Plymouth Meeting

Quintiles, Inc. Opens Expanded Asia-Pacific Headquarters in Singapore; Potential to More than Double Singapore Workforce

FDA Approves Gloucester Pharmaceuticals, Inc.'s ISTODAX(R) for Patients with Cutaneous T-cell Lymphoma

New Gene Therapy Halts 2 Boys' Rare Brain Disease, Study
AP -- French scientists mixed gene therapy and bone marrow transplants in two boys to seemingly halt a brain disease that can kill by adolescence. The surprise ingredient: They disabled the HIV virus so it couldn't cause AIDS, and then used it to carry in the healthy new gene. The experiment marks the first time researchers have tried that long-contemplated step in people and the first effective...

Genes Linked to 'Pot' Belly, University of Texas Southwestern Medical Center Study
HealthDay News -- New research sheds light on the possible link between the genes you inherit and the size of your belly.

Dutch Pull Pfizer Inc. Vaccine Batch, Prevenar, After Infants Die

Stanford University Medical Center Study Shows Neural Stem Cells In Mice Affected By Gene Associated With Longevity
EurekAlert -- A gene associated with longevity in roundworms and humans has been shown to affect the function of stem cells that generate new neurons in the adult brain, according to researchers at the Stanford University School of Medicine. The study in mice suggests that the gene may play an important role in maintaining cognitive function during aging.

Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer, University of Rochester Medical Center Study
EurekAlert -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. While key experiments were in animals, the...

Graceway Pharmaceuticals, LLC Acquires Worldwide Rights to GS 9191 from Gilead Sciences, Inc.

Cause Of Common Chronic Diarrhea Revealed In New Research, Imperial College London, King's College London, and University of Edinburgh Study
ScienceDaily (Nov. 6, 2009) A common type of chronic diarrhea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology. The authors of the paper, from Imperial College London, with collaborators from King's College London and the University of Edinburgh, say their results could help more doctors recognise this type...

FDA Approves Labeling Update for Bristol-Myers Squibb Company's REYATAZ(R) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long-term data from the CASTLE Study. The CASTLE Study assessed a once-daily REYATAZ/ritonavir (REYATAZ/r)-based regimen versus a twice-daily lopinavir/ritonavir (LPV/r)-based regimen in previously untreated...

Lonza Group Ltd. Buys AlgoNomics

Finding May Help Some Tonsil Cancer Patients Avoid Chemotherapy, Study
ScienceDaily (Nov. 6, 2009) Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. For some patients, this may mean successful treatment with radiation alone and avoiding the side effects of chemotherapy...

Abbott Laboratories Loss to Johnson & Johnson Upheld in $1.7 Billion Patent Suit

RXi Pharmaceuticals Appoints as CEO

Brainwave Sofa Is Exactly What You Were Thinking
medGadget -- Ever wondered what a piece of furniture formed from raw data extracted from your brain would look like? But of course you have, and so did Lucas Maassen and Dries Verbruggen, the designers of the Brainwave Sofa.

Outrage as Doctors' Group Allows Coca-Cola to Sponsor Health Advice
Advice about soft drinks and health from one of the nation's largest doctors groups will soon be brought to you by Coke.The American Academy of Family Physicians has prompted outcry and lost members over its new six-figure alliance with the Coca-Cola Co. The deal will fund educational materials about soft drinks for the academy's consumer health and wellness Web site, www.FamilyDoctor.org.

Complete Horse Genome Sequence Revealed, University of California, Davis (UCD) Study
HealthDay News -- The genome of the domestic horse has been sequenced, an accomplishment that will improve the breeding of horses and may help studies of human health, according to an international team of researchers.

Par Pharmaceutical, Inc. Q3 Profit Beats Estimates on Strong Revenue

TiGenix Says May Raise Capital to Fund Growth

Complete Genomics, Inc. Sequences Whole Human Genome for $1,700

Sleep Apnea Therapy Improves Golf Game, Study
Men Find New Motivation for Using CPAP

SAN DIEGO, Nov. 2 /PRNewswire-USNewswire/ -- Golfers who undergo treatment forsleep apnea may improve their golf game as well as their overall health, showsnew research. A new study presented at CHEST 2009, the 75th annualinternational scientific assembly of the American College of Chest Physicians(ACCP), found that golfers with obstructive...

Johnson & Johnson to Close Two Philadelphia Area Sites
Philly.com -- Johnson & Johnson said today that it was closing research & development facilities in Radnor and Chesterbrook and consolidating those operations at the company's Spring House site.

Oral Contraceptives May Benefit Women with Asthma, McMaster University Study
EurekAlert -- New research shows that during natural menstrual cycles, women with asthma who were not taking oral contraceptives (OC) had lower exhaled nitric oxide levels (eNO), a marker of airway inflammation associated with asthma, than women who were taking OC. Researchers from McMaster University in Hamilton, ON, Canada, studied 17 women with asthma during their menstrual cycles. Results showed...

Danish Biotech Genmab A/S to Reorganize, to Sell U.S. Plant and Cut 300 Jobs

Folic Acid Supplements Linked To Asthma, Study Suggests
ScienceDaily (Nov. 4, 2009) A University of Adelaide study may have shed light on the rise in childhood asthma in developed countries like Australia in recent decades. Researchers from the University's Robinson Institute have identified a link between folic acid supplements taken in late pregnancy and allergic asthma in children aged between 3 and 5 years, suggesting that the timing of supplementation...

Experimental Vaccine Cures Pre-Cancer Vulvar Growths, Leiden University Medical Center Study
Reuters - An experimental vaccine cured nearly half of women with pre-cancerous growths on their genitals, producing major improvement in nearly four out of five, researchers in the Netherlands reported on Wednesday.

Discovery Laboratories Says to Look for Pipeline Funding

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer; Fails to Meet Secondary Endpoint of Overall Survival

Lung Tissue Generated From Human Embryonic Stem Cells, Vrije Universiteit Brussel Study
ScienceDaily (Nov. 5, 2009) Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface. The technique, published in BioMed Central's open access journal Respiratory Research, could provide an alternative to lung transplants for patients with lung injury due to chronic pulmonary disease...

Metabolex, Inc. Closes $8.6 Million Financing Round

Merck & Co., Inc. CEO "Actively Looking" for Biotech Deals

GenVec Inc. Cancer Drug Gets Orphan Status

Gene Discovery Gives Clues to Crohn's Disease, Colitis, University College London Study
MedPage Today -- Genetic mutations in interleukin-10 receptors may be responsible for inflammatory bowel disease in patients who inherit the disorder, researchers said. In an analysis of two children who had early onset of the disease and their families, the researchers found mutations in genes encoding the IL10R proteins, which make up interleukin-10 receptors, according to Erik-Oliver Glocker, MD...

Zyngenia Raises $10 Million in Series A Funding

Merck & Co., Inc. CEO Plans to Keep Schering-Plough Corporation Headquarters
Bloomberg -- Merck & Co. Chief Executive Officer Richard T. Clark said he plans to keep Schering-Plough Corp.s headquarters after completing the acquisition of the company.

Cardinal Health, Inc. Posts Net Loss Due to Costs of Spinoff

Biovail Corporation Profit Lower on Restructuring Charges

King Pharmaceuticals??, Inc. Reports Profit Fall

Pfizer Inc. Jury Said to Award $75 Million Prempro Verdict to Woman
Bloomberg -- Pfizer Inc. must pay about $75 million in punitive damages to an Illinois woman who developed cancer after taking one of the drugmakers menopause treatments, people familiar with a sealed verdict in the case said.

Astellas Pharma Inc. Cuts Outlook as Generic Competition Heats Up

New Merck & Co., Inc. Begins Operations Worldwide; Now No. 2 Drugmaker, Set for Future Buys

FDA Won't Accept Merck & Co., Inc.'s Application for New Drug

FDA Approves Nuvo Research Inc., Covidien's Pennsaid(R) Topical Solution

Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Phase 2 Data of Investigational Drug, Hematide, Suggest Its Ability to Restore Hemoglobin in Patients With Pure Red Cell Aplasia
PALO ALTO, Calif., & DEERFIELD, Ill.--(Business Wire)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research &Development Center, Inc., today announced data from a Phase 2 clinical trial ofHematide showing that Hematide increased hemoglobin and reduced or eliminatedthe need for blood transfusion in most patients with erythropoietin-induced purered cell aplasia (PRCA). The...

How Much Egg Sensitivity Makes a Flu Shot Dangerous for Your Child?
Newswise My three year old had a skin breakout we think was due to eggs is it safe to do a flu shot? Its a question being asked to every doctor who takes care of kids during flu season. On the one hand we are concerned about the devastating effects of the new strain of flu, and on the other we arent sure if a history of eggs sensitivity is enough to hold the shot or spray, said Bobby Q. Lanier...

Pet Cat in U.S. Catches Swine Flu
Reuters A cat in Iowa has tested positive for H1N1 swine flu, the first time a cat has been diagnosed with the new pandemic strain, the American Veterinary Medical Association said on Wednesday. The 13-year-old cat apparently caught the virus from one of the people living in the house, the group said in a statement. It has recovered and does not appear to have infected anyone or anything else....

Breast Cancer Vaccine Tests German Merck KGaA's $1 Billion Strategy

Biovitrum AB and Swedish Orphan AB Combine to Form

Green Tea Shows Promise As Chemoprevention Agent For Oral Cancer, University of Texas MD Anderson Cancer Center Study Finds
EurekAlert -- Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center. The study, published online in Cancer Prevention Research, is the first to examine green tea as a chemopreventative agent in this high-risk patient population...

Acetaminophen May Be Linked To Asthma In Children And Adults, University of British Columbia Study
EurekAlert -- New research shows that the widely used pain reliever acetaminophen may be associated with an increased risk of asthma and wheezing in both children and adults exposed to the drug. Researchers from the University of British Columbia, Vancouver, BC, Canada, conducted a systematic review and metaanalysis of 19 clinical studies (total subjects425,140) that compared the risk of asthma or...

Two Genes Cooperate To Cause Aggressive Leukemia, University of Gothenburg Study
EurekAlert -- Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.

Statins May Worsen Symptoms In Some Cardiac Patients, Northeastern University and Massachusetts General Hospital Study
EurekAlert -- Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects...

CARBOGEN AMCIS Announces Company Restructure; 40 Positions Across Swiss Operations to be Lost
BUBENDORF, Switzerland -- CARBOGEN AMCIS announced its intention to restructure its Swiss operations. The early phase services, currently provided by its facilities in canton Aargau, will be consolidated at the Aarau site. The Hunzenschwil site will focus on new technologies, such as micro-reactors, crystallisation and the using the unique assets of the site. In addition, the late phase and high...

ALZA Corporation Faces Layoffs in Vacaville, California

New Activity Found For A Potential Anti-cancer Agent From Marine Sponges, Texas A&M University and Johns Hopkins University Study
ScienceDaily (Nov. 3, 2009) Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers...

Coffee And Nighttime Jobs Don't Mix, University Of Montreal Study Finds
ScienceDaily (Nov. 4, 2009) Night-shift workers should avoid drinking coffee if they wish to improve their sleep, according to research published in the journal Sleep Medicine. A new study led by Julie Carrier, a Universit de Montral psychology professor and a researcher at the affiliated Hpital du Sacr-Cur Sleep Disorders Centre, has found the main byproduct of coffee, caffeine, interferes...

Johnson & Johnson to Cut 7,000-8,000 Jobs in Restructuring

Estrogen And Stroke Risk: Long Period Of Estrogen Deprivation Can Lead To Loss Of Sensitivity And Protective Effects In The Brain, Medical College of Georgia, University of Texas Health Science Center, and Study
ScienceDaily (Nov. 4, 2009) Eighteen years ago this month the National Institutes of Health (NIH) announced that it would sponsor a landmark study to examine women and cardiovascular disease. Known as the Women's Health Initiative (WHI), the study enrolled more than 161,000 women. By 2004 however, the government had ended two arms of the study involving estrogen after researchers found it posed a...

University of California, Los Angeles (UCLA) Researchers Reconstitute Enzyme That Synthesizes Cholesterol Drug Lovastatin
EurekAlert -- Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.

Stiefel Laboratories Closing Coral Gables Headquarters; Layoff 40

FDA Grants Priority Review for Shire plc's Velaglucerase Alfa for Type 1 Gaucher Disease; PDUFA Date is February 28, 2010

Student Dissertation Launches San Diego Life Sciences Tools Company, Sirigen Inc.

Cevec Pharma Raises Eur 4 Million

Flamel Technologies Announces Licensing Agreement with Pfizer Inc.

American Regent, Inc. Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials

Novartis Corporation Buys Stake in China Vaccine Company, for $125 Million

King Pharmaceuticals??, Inc. Sues ZymoGenetics, Inc. Alleging Trademark Violation

Omnicare, Inc., Teva Pharmaceutical Industries Limited Unit Pay $112 Million for Kickbacks

Singapore Roche Plant to Create 100 Jobs

Study Points To New Uses, Unexpected Side Effects Of Already-Existing Drugs, University of North Carolina and University of California, San Francisco (UCSF)
UNC -- Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs. The researchers developed a computational method that compares how similar the structures of all known drugs are to the naturally occurring binding partners -- known...

Low Cholesterol May Help Prevent Cancer, National Cancer Institute Study
HealthDay News -- Low blood cholesterol levels reduce the risk not only of heart disease but also of cancer, two new studies show. The findings should help ease longstanding fears that low cholesterol is associated with an increased risk of cancer, said Dr. Demetrius Albanes, a senior investigator at the U.S. National Cancer Institute, and an author of one of two reports in the November issue of Cancer...

New GlaxoSmithKline, Pfizer Inc. Company Launches; New Specialist HIV Company Dedicated to Delivering Advances in HIV Treatment and Care

Children Who Often Drink Full-fat Milk Weigh Less, University of Gothenburg Research Finds
ScienceDaily (Nov. 4, 2009) Eight-year-old children who drink full-fat milk every day have a lower BMI than those who seldom drink milk. This is not the case for children who often drink medium-fat or low-fat milk. This is one conclusion of a thesis presented at the Sahlgrenska Academy.

Heart Attack Myth: Women Do Have Same The Heart Attack Symptoms As Men, Canadian Institutes Of Health Research Study Shows
ScienceDaily (Nov. 3, 2009) The gender difference between men and women is a lot smaller than we've been led to believe when it comes to heart attack symptoms, according to a new study presented to the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

Common Pain Relievers May Dilute Power Of Flu Shots, University of Rochester Medical Center Study
ROCHESTER, N.Y., Nov. 3 /PRNewswire-USNewswire/ -- With flu vaccination seasonin full swing, research from the University of Rochester Medical Centercautions that use of many common pain killers -- Advil, Tylenol, aspirin -- atthe time of injection may blunt the effect of the shot and have a negativeeffect on the immune system.

Richard P. Phipps, Ph.D., professor of Environmental...

Hemispherx Biopharma Responding to FDA's Ampligen Questions

Drug Company-sponsored Events For Health Professionals Fail To Disclose Financial Ties, Analysis Finds
ScienceDaily -- ScienceDaily (Nov. 3, 2009) Australian reporting standards for disclosing the ties between pharmaceutical companies and health professionals are not comprehensive enough, according to an analysis in this week's PLoS Medicine.

New Genetic Cause Of A Fatal Immune Disorder, Research
EurekAlert -- Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, fatal, immune disorder characterized by uncontrolled activation of immune cells known as lymphocytes and macrophages. Disease-causing mutations have been identified in several genes that generate proteins involved in lymphocyte-mediated cell death, including syntaxin-11. Now, Genevive de Saint Basile and colleagues, at...

Certain Antibiotics May Up Birth Defect Risk, Centers for Disease Control and Prevention (CDC) Study
ScienceDaily (Nov. 3, 2009) Penicillin and several other antibacterial medications commonly taken by pregnant women do not appear to be associated with many birth defects, according to a report in the November issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. However, other antibiotics, such as sulfonamides and nitrofurantoins, may be associated with several...

Nicotine Patch Plus Lozenge Best for Quitting Smoking, National Institutes of Health (NIH) Funded Study
WebMD -- Smokers who want to kick the habit are more likely to succeed when they use a combination of long-acting and immediate-delivery nicotine-replacement products, a study shows. Study participants who used nicotine patches plus nicotine lozenges were more successful than participants who used either product alone. They also had better outcomes than those who used the smoking-cessation drug Zyban...

Processed Food Increases Depression Risk, University College London Study
UPI -- Eating a lot of processed food may increase a person's risk for depression, researchers in Britain found. Tasnime N. Akbaraly, Eric J. Brunner, Jane E. Ferrie, Michael G. Marmot and Mika Kivimak of the University College London analyzed data from 3,486 participants -- 26.2 percent women, mean age 55.6 years -- from the Whitehall II prospective study. Two dietary patterns were identified in the...

FDA Denies Approval for GTx, Inc. Drug; Seeks Additional Study

Novartis International AG to Invest $1 Billion in China

Developmental Drug May Help Bone Fractures Heal After Radiation Exposure, University of Pittsburgh School of Medicine Study
ScienceDaily (Nov. 3, 2009) A drug currently under development by the University of Pittsburgh School of Medicine may help bone fractures heal more quickly after radiation exposure, according to a study by Pitt researchers.

Ironwood and Forest Laboratories, Inc. Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation; Top-line Results Show Each Trial Met Primary and All Secondary Endpoints

Eli Lilly and Company Reducing Sales Force By 191 as Part of Larger Restructuring

Osiris Therapeutics, Inc. Achieves $15 Million Milestone Payment from NuVasive, Inc.

Quintiles, Inc. Inks Pharma Deal with AstraZeneca PLC

Possible Origins Of Pancreatic Cancer Revealed by Massachusetts Institute of Technology (MIT) Biologists
EurekAlert -- Study results: MIT cancer biologists have identified a subpopulation of cells that can give rise to pancreatic cancer. They also found that tumors can form in other, more mature pancreatic cell types, but only when they are injured or inflamed, suggesting that pancreatic cancer can arise from different types of cells depending on the circumstances.

World's Largest Malaria Vaccine Trial Now Underway In 7 African Countries, GlaxoSmithKline Biologicals Study
EurekAlert -- A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral...

Verenium Corporation and Close Research Collaboration; Portfolio of Development Candidates Strategically Divided Between Companies

Takeda Pharmaceuticals North America, Inc. Establishes Expanding Presence in North America

US FDA Issues Alert on Kidney Problems with Eli Lilly and Company , Amylin Pharmaceuticals, Inc.'s Byetta

U.S. Seeks More Information on MDS Analytical Technologies-Danaher Deal

Bristol-Myers Squibb Company, Sanofi-Aventis (France) Prevail in Fight Over Plavix

West Pharmaceutical Services Q3 Lags Estimates, to Cut 100 Jobs

Merck & Co., Inc. and Schering-Plough Corporation to Complete Merger Today; New Will Begin Combined Operations Tomorrow

XOMA (US) LLC Signs Antibody Discovery Collaboration With Kaketsuken; to Get $8 Million

Speed Limit To The Pace Of Evolution, University of Pennsylvania Biologists Say
ScienceDaily (Nov. 3, 2009) Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits." The model provides quantitative predictions for the speed of evolution on various "fitness landscapes," the dynamic and varied conditions under which...

Pancreatic Cancer: Discovery Offers Potential New Treatment, Ohio State University Study
ScienceDaily (Nov. 3, 2009) Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard...

Iowa State University Researchers' Findings Bring Hope for Possible Parkinson's Disease Cure
ISU -- Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others. Anumantha Kanthasamy, a distinguished professor of biomedical sciences and W. Eugene and Linda R. Lloyd Endowed Chair in Neurotoxicology at the ISU College of Veterinary Medicine, has been working to understand the complex mechanisms of the disease for more than...

Vision of the Future: Custom Corneas
Discovery -- NASA technology that allows the Hubble telescope to focus on distant stars now offers LASIK eye surgery patients customized options for fine-tuned night vision, superior image contrast and sight even beyond 20/20.

Anemia Drug May Raise Stroke Risk in Kidney Patients, Brigham and Women's Hospital Study
San Diego Union Tribune -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.

Amylin Pharmaceuticals, Inc. Strikes $1 Billion Deal with Takeda Pharmaceutical Co. Ltd. to Co-Develop Weight Loss Drugs

First Draft of the Pig: Researchers Sequence Swine Genome, University of Illinois Study
EurekAlert -- A global collaborative has produced a first draft of the genome of a domesticated pig, an achievement that will lead to insights in agriculture, medicine, conservation and evolution. A red-haired Duroc pig from a farm at the University of Illinois will now be among the growing list of domesticated animals that have had their genomes sequenced. Researchers will announce the achievement...

Next-generation Microcapsules Deliver 'Chemicals On Demand', University of California, Berkeley (CAL) and Lawrence Berkeley National Laboratory Research
ScienceDaily (Nov. 2, 2009) Scientists in California are reporting development of a new generation of the microcapsules used in carbon-free copy paper, in which capsules burst and release ink with pressure from a pen. The new microcapsules burst when exposed to light, releasing their contents in ways that could have wide-ranging commercial uses from home and personal care to medicine.

Can Charcoal Fight Heart Disease In Kidney Patients?
ScienceDaily (Oct. 31, 2009) Charcoal may provide a new approach to managing the high rate of heart disease in patients with advanced kidney disease, according to preliminary research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

Unexpected Consequences Of Proton Pump Inhibitor Use In Reflux Disease
Medical News Today -- Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology -Head and Neck Surgery...

Perrigo Company Divests Israel Business for 205 Million New Israeli Shekels (US $54 Million)

Genetic Links To Fungal Infection Risk Identified, University College London and Study
EurekAlert -- Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments. The two separate studies, published today in the New England Journal of Medicine, mark a significant step...

Amylin Pharmaceuticals, Inc. Says Byetta Gets FDA Approval for New Use

Pfizer Inc. Eyes Deal with Israel's Protalix Biotherapeutics

Alternatively Spliced Tissue Factor Identified As Promising New Biomarker For Aggressive Cancers, University of Cincinnati and Leiden University Medical Center Study
ScienceDaily (Nov. 1, 2009) A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.

FDA Concerns Remain Over New Use for Schering-Plough Corporation Drug, PegIntron

Human Genome Sciences, Inc. , GlaxoSmithKline Lupus Drug Works in 2nd Trial

Eisai Inc. : Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival

WOODCLIFF LAKE, N.J., Oct. 30 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

This global Phase III study, known as "EMBRACE," (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice...

Switching Immunosuppressants Reduces Cancer Risk In Kidney, Queen Elizabeth Hospital Study
ScienceDaily (Oct. 31, 2009) Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

Extending Treatment After Liver Transplant May Benefit Patients With Hepatitis C Recurrence, Henry Ford Hospital Study
Henry Ford Health -- Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

LFB Biotechnologies Provides $10 Million of Funding To GTC Biotherapeutics

Pulmatrix Closes $30.2 Million in Series B Financing

Cequent Pharmaceuticals, Inc. Closes Tranche of $10.8 Million Round
Boston Business Journal -- Cambridge-based biotechnology company Cequent Pharmaceuticals has raised $2.7 million of a planned $10.8 million financing round. The funding included investments from Wellesley, Mass.-based Ampersand Ventures, New England Capital Partners in Newton, Mass., and Durham, N.C.-based A.M. Pappas Life Science Ventures.

Bellicum Pharmaceuticals, Inc. Raises $4.5 Million
pehub.com -- Bellicum Pharmaceuticals Inc., a Houston-based drug startup focused on prostate cancer, has raised $4.5 million in Series A and convertible note financing. The company has now raised a total of $8.5 million, including $1.45 million from the Texas Emerging Technology Fund.

 

Abraxis BioScience, Inc. Opens $70 Million Phoenix Manufacturing Site; Will Create up to 200 Technology Jobs

IMS Health to be Sold for $5.2 Billion, Employs 1,000 in Plymouth Meeting

Quintiles, Inc. Opens Expanded Asia-Pacific Headquarters in Singapore; Potential to More than Double Singapore Workforce

FDA Approves Gloucester Pharmaceuticals, Inc.'s ISTODAX(R) for Patients with Cutaneous T-cell Lymphoma

Dutch Pull Pfizer Inc. Vaccine Batch, Prevenar, After Infants Die

Graceway Pharmaceuticals, LLC Acquires Worldwide Rights to GS 9191 from Gilead Sciences, Inc.

FDA Approves Labeling Update for Bristol-Myers Squibb Company's REYATAZ(R) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long-term data from the CASTLE Study. The CASTLE Study assessed a once-daily REYATAZ/ritonavir (REYATAZ/r)-based regimen versus a twice-daily lopinavir/ritonavir (LPV/r)-based regimen in previously untreated...

Lonza Group Ltd. Buys AlgoNomics

Abbott Laboratories Loss to Johnson & Johnson Upheld in $1.7 Billion Patent Suit

RXi Pharmaceuticals Appoints as CEO

Par Pharmaceutical, Inc. Q3 Profit Beats Estimates on Strong Revenue

TiGenix Says May Raise Capital to Fund Growth

Complete Genomics, Inc. Sequences Whole Human Genome for $1,700

ZIOPHARM Oncology, Inc. Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. As previously announced, having achieved the study-specified efficacy milestone...

Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

PARIS, November 6 /PRNewswire/ --

- Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that...

Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at Annual Meeting

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled...

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS(R) continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA:

Continuous Subcutaneous Delivery of Exenatide Via ITCA 650 Lowers Plasma Glucose, HbA...

Threshold Pharmaceuticals, Inc. Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting
REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009.

XOMA (US) LLC Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
BERKELEY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to...

Genetix Pharmaceuticals, Inc. Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD)
CAMBRIGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the companys clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM). Genetix is planning...

Puredel Limited Release: Ossulin(TM) Oral Insulin Data to be Presented at The San Francisco Diabetes Congress on November 6, 2009
LONDON--(BUSINESS WIRE)--The first public data on Ossulin a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited (www.cmdpharmaltd.com) and Natreon Inc., New Brunswick, NJ., developers of the proprietary...

Chimerix, Inc. Updates the World Health Organization and the on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox

RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a broad-spectrum antiviral...

NexBio, Inc. Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses

SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong, announced today the publication of two articles in the peer-reviewed journal PLoS ONE. These two published studies suggest that DAS181 (Fludase(R)) may play a potentially important role for the treatment...

EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus

VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.

The agreement gives EUCODIS Bioscience exclusive access - for the search of enzymes of interest...

PPD, Inc. Completes Acquisition of
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China. The acquisition strengthens PPDs full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia...

RiskMetrics Recommends Stockholders Vote ???FOR??? Life Sciences Research, Inc./Merger
EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today that RiskMetrics Group (formerly Institutional Shareholder Services), a leading proxy advisory firm, has recommended that LSR stockholders vote FOR the approval of the merger of LSR and Lion Merger Corp. pursuant to the Agreement and Plan of Merger, dated as of July 8, 2009, among LSR, Lion Merger...

Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus

SPRING VALLEY, Calif., Nov. 6 /PRNewswire/ -- Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.

Technology developed...

Theravance, Inc. and Astellas Pharma Inc. Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States

(Click here for details)

SOUTH SAN FRANCISCO, CA and DEERFIELD, IL--(Marketwire - November 05, 2009) - Theravance, Inc.(NASDAQ:

BioMarin Pharmaceutical Inc.: United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food

NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan(R) (sapropterin dihydrochloride) with food for the treatment of phenylketonuria (PKU). The patent expires in 2024.

About Kuvan

Kuvan has received...

Biostar Pharmaceuticals, Inc. Announces Closing of a $3.6 Million Equity Financing

Delisting of Securities of Hana Biosciences, Inc. From The Stock Market
NEW YORK, Nov. 5, 2009 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Hana Biosciences, Inc. Hana Biosciences, Inc.'s stock was suspended on September 10, 2009 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after...

Locus Pharmaceuticals, Inc. Announces Focus on Drug Discovery Collaboration Business,
BLUE BELL, Pa.--(BUSINESS WIRE)--Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel. Ansaris...

Althea Technologies, Inc. Adds Formulation Development to Its Integrated Offering of Contract Services

SAN DIEGO, Nov. 5 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development. This investment in an experienced...

Achillion Pharmaceuticals, Inc. Reports Third Quarter Results
NEW HAVEN, Conn., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $6.4 million, compared with a...

Aceto Corporation Announces Fiscal 2010 First Quarter Results of Operations
LAKE SUCCESS, N.Y., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of chemically derived pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2010 first quarter ended September 30, 2009.

Athersys, Inc. Reports 2009 Third Quarter Results
CLEVELAND, Nov. 5, 2009 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended September 30, 2009. Third Quarter Highlights Include:

Alkermes Reports Second Quarter Fiscal 2010 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its second quarter of fiscal 2010, which ended on September 30, 2009.

Sucampo Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of 2009
BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today reported its consolidated financial results for the quarter and nine months ended September 30, 2009.

Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2009
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the third quarter and nine months ended September 30, 2009.

Ardea Biosciences, Inc. Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009.

(Logo: http://www.newscom.com/cgi...

Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2010 Financial Results
ANN ARBOR, Mich., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today reported financial results and operational updates for the first fiscal quarter ended September 30, 2009. Aastrom continues to operate in a capital-efficient manner while advancing its cardiovascular clinical...

BioSpecifics Technologies Corporation Reports Third Quarter 2009 Financial Results

LYNBROOK, N.Y., Nov. 5 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. , a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

"We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommended, by a vote of...

BioMimetic Therapeutics, Inc. Reports 2009 Third Quarter Earnings Results
FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and nine months ended September 30, 2009. For the three months ended September 30, 2009, the Company reported a net loss of $7.9 million, or $0.36 per diluted share, compared to a net loss of $18.0 million, or $0.97 per diluted share, for the same period in 2...

Bioniche Pharma Ltd. Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement

BELLEVILLE, ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

"We ended the first quarter of Fiscal 2010 in a strong position, with current assets of $25.3 million, 53% of which is cash," stated...

BIOLASE Technology, Inc. Reports Third Quarter, Nine-Month Results

IRVINE, CA--(Marketwire - November 05, 2009) - BIOLASE Technology, Inc. (NASDAQ: BLTI), theworld's leading dental laser company, today reported operating results forthe 2009 third quarter and nine months ended September 30, 2009.

Net revenue for the third quarter of 2009 was $12.1 million, compared...

Cadence Pharmaceuticals, Inc. Reports Third Quarter 2009 Financial Results

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009.

Financial Results

For the three months ended...

BioNovo, Inc. Announces Third Quarter 2009 Highlights and Financial Results

EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. , a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced third quarter highlights and financial results for the three months ended September 30, 2009.

Subsequent to the end of the quarter, in October 2009, Bionovo successfully completed a public offering and...

Celsion Corporation to Hold Third Quarter 2009 Financial Results Conference Call Tuesday, November 10, 2009
COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ:CLSN), a late stage clinical oncology development company that is leveraging its heat activated liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it will hold a conference call to discuss third quarter 2009 results at 11:00 a.m. Eastern Time on Tuesday, November ...

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results Q3 Domestic PDT

WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R) , a dermatology company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the third quarter ended September 30, 2009.

Third quarter and year-to-date...

Evotec AG to Report Third Quarter 2009 Results on 12 November 2009
HAMBURG, Germany, Nov. 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (Nasdaq:EVTC) will report its financial results for the third quarter of 2009 on Thursday, 12 November 2009.

GTC Biotherapeutics Reports Third Quarter 2009 Financial Results
FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.s ("GTC", NASDAQ: GTCB) total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share...

GenVec Inc. Reports Third Quarter 2009 Financial Results

GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. today announced its financial results for the third quarter ended September 30, 2009. GenVec reported a net loss of $3.6 million ($0.04 per share) for the three months ended September 30, 2009 compared to a net loss of $6.8 million ($0.08 per share) in the comparable quarter of 2008. For the nine months ended September 30, 2009, GenVec...

GeoVax Labs Inc. Provides Third Quarter 2009 Financial Results and Operational Update

ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

Robert McNally, Ph.D., President and Chief...

Halozyme Therapeutics, Inc. Reports Third Quarter 2009 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

Immunomedics, Inc. Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
MORRIS PLAINS, N.J., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the first quarter ended September 30, 2009. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

Helix BioMedix, Inc. Reports Third Quarter 2009 Financial Results
BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2009.

Inhibitex, Inc. Reports Third Quarter 2009 Financial Results
ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.

InterMune, Inc. Reports Third Quarter 2009 Financial Results and Business Highlights

BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced results from operations for the third quarter and nine months ended September 30, 2009. InterMune reported a net loss for the third quarter of 2009 of $8.8 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.36 per share, in the third quarter of 2008.

Dan Welch, Chairman, Chief...

Insmed Incorporated Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009

RICHMOND, Va., Nov. 6 /PRNewswire-FirstCall/ -- Insmed Inc. , a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2009.

The net loss for the third quarter of 2009 was $150,000; break even on a dollar per share basis, compared with a net loss of $2.2 million, or $0.02 per share, in the third quarter of 2008. This...

Jazz Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results -Achieved Record Quarterly Net Product Sales of $30 Million - Raising Revenue Guidance for 2009

PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2009.

"Our sales team delivered another solid quarter for us with record numbers of XYREM and LUVOX CR prescriptions and net sales" said Bob Myers, President of Jazz Pharmaceuticals.

Jazz...

Ligand Pharmaceuticals Inc. Announces Third Quarter Results
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the Company or Ligand) today announced financial results for the three and nine months ended September 30, 2009 and provided a business update.

Labopharm Reports Results for Third Quarter Fiscal 2009

LAVAL, QC, Nov. 6 /PRNewswire-FirstCall/ - Labopharm Inc. today reported its financial results for the third quarter ended September 30, 2009. All figures are in Canadian dollars unless otherwise stated.

"We have made strong progress in recent months towards the commercialization of our novel trazodone formulation in both the United States and Canada," said James R. Howard...

Life Sciences Research, Inc. Announces Third Quarter Results
EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today financial results for the three and nine months ended September 30, 2009.

Maxygen, Inc. Reports Third Quarter 2009 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced financial results for the quarter ended September 30, 2009.

Nabi Biopharmaceuticals Announces Third Quarter 2009 Financial Results
ROCKVILLE, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the quarter ended September 26, 2009. The Company reported a net loss from continuing operations of $7.0 million, or $0.14 per share, compared to a net loss of $4.6 million, or $0.09 per share, for the period ended September 27, 2008.

Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. The Company also announced its analysis of results from a previously suspended Phase 2 study of aplindore in Restless Legs Syndrome (RLS) and...

Novavax, Inc. Reports Third Quarter 2009 Financial Results

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones.

Novavax's net loss for the third quarter of 2009 was $7.5 million, or $0.08 per share, compared to a net loss of $7.8 million, or $0.12 per share, for the same period last year...

NeurogesX, Inc. Reports Third Quarter 2009 Results Conference Call Today at 9am ET

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --

3Q09 Corporate Highlights:

Upcoming 2009 Milestones:

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009.

During the third quarter of 2009, NeurogesX...

Novadaq Corp. Expands Q3-09 Financial Results Conference Call to Include Live Webcast

TORONTO, ONTARIO--(Marketwire - November 05, 2009) - Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for the operating room, announced today that it is expanding the scope of its Q3-2009 financial results conference call, scheduled for November 12, 2009 at 1...

Osteotech, Inc. Reports Third Quarter 2009 Financial Results Company Achieves Sequential and Year-Over-Year U.S. Sales Growth In Base Business 2009 Guidance Updated Call on November 6, 2009 at 9:00 a.m. EST

EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Osteotech, Inc. , a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the third quarter ended September 30, 2009.

"During the third quarter of 2009, our focus was on the release of our three new biologic products MagniFuse(TM) Bone Graft, FacetLinx(TM) Fusion Technology...

OncoGenex Pharmaceuticals Inc. Reports Third Quarter 2009 Financial Results

Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.

The following...

Par Pharmaceutical, Inc. Reports EPS of $0.76 for Third Quarter 2009 Achieves Record Quarterly Gross Margin of $92 Million

WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today reported results for the third quarter ended October 3, 2009.

For the third quarter ended October 3, 2009, Par reported total revenues of $294.8 million and net income of $26.3 million, or $0.76 per diluted share. This is compared to reported revenues of $149.0 million and net income of...

Spectrum Pharmaceuticals, Inc. Announces Date for Third Quarter 2009 Corporate Update and Pipeline Review Conference Call
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced the date and time for its third quarter 2009 corporate update and pipeline review conference call.

Somaxon Pharmaceuticals, Inc. Reports 2009 Third Quarter Financial Results
SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the third quarter...

Stellar Pharmaceuticals Inc.'s Q3-2009 Financial Results Marked by Strong Growth and Continued Profitability

LONDON, ONTARIO--(Marketwire - November 06, 2009) - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced its financial results for the third quarter...

Threshold Pharmaceuticals, Inc. Reports Third Quarter 2009 Financial Results
REDWOOD CITY, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009.

Transcept Pharmaceuticals, Inc. to Report Third Quarter 2009 Results and Host Conference Call on November 12

POINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will host a webcast and teleconference with management to discuss third quarter 2009 financial results...

Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2009 Financial Results

SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. today announced financial results for its third quarter and nine months ended Sept. 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Third Quarter and Nine Months 2009 Financial Results

Revenue for the third quarter and nine months ended Sept. 30, 2009, was $4.5 million...

Targacept, Inc. Reports Third Quarter 2009 Financial Results
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today reported its financial results for the third quarter ended September 30, 2009.

ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line

RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. , a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the first quarter of fiscal 2010.

For the quarter ended September 30, 2009, the Company reported revenues of $5.2 million, a 15 percent increase over revenues of $4.5 million in the first quarter...

ZymoGenetics, Inc. Reports Third Quarter 2009 Financial Results
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported improved financial results for the third quarter ended September 30, 2009. The companys net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008. Revenues for the third quarter of 2009 increased by 131% compared to the third quarter...

Amarin Corporation PLC Appoints as Chief Financial Officer
DUBLIN--(BUSINESS WIRE)--Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of John F. Thero as the Companys Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate development and other strategic and operational matters. He will report directly to Dr. Declan Doogan...

TARIS Biomedical Appoints to CMO Post
LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the appointment of Julie Lekstrom Himes, M.D. to join TARIS in the position of Chief Medical Officer and Senior Vice President for Clinical Development. Dr. Himes has broad clinical research and operations experience within the...

EpiCept Corporation Names as Senior Vice President, Sales and Marketing
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has appointed Bernard R. Tyrrell as the Companys Senior Vice President, Sales and Marketing, a newly created position. Mr. Tyrrell joins EpiCept with a wealth of experience in pharmaceutical marketing and business development, both in the U.S. and internationally. Most...

Emisphere Technologies, Inc. Appoints to the Board of Directors
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Companys Board of Directors effective immediately. Mr. Rothwells appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain other business endeavors...

Washington Biotechnology & Biomedical Association???s New ???Healthcare Economics in WA??? Breaking News is Powered by
REDMOND, Wash.--(BUSINESS WIRE)--Visitors to the newly branded and redesigned website of the Washington Biotechnology & Biomedical Association (WBBA) to be featured at the WBBAs Annual Meeting today will get free, timely, Washington state-focused biotech and medtech news through its Economic Issues in WA Healthcare Breaking News feature. This new feature, powered by MedIntelliBase Intelligence...

Purdue Research Foundation to Recognize 32 Faculty and Staff Entrepreneurs, Inventors
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Thirty-two Purdue University faculty and staff will be recognized at the Purdue Research Foundation's annual Inventors Recognition Dinner on Thursday (Nov. 5).

Phase Forward Named Private Sector Company of the Year by
WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the Mass Technology Leadership Council, Inc. named Phase Forward Private Sector Company of the Year at the 2009 Mass Technology Leadership Awards in Boston last night. Honoring Massachusetts companies and individuals who best exemplify leadership...

Laboratory Corporation of America Holdings (LabCorp) is Scheduled to Present at the 18th Annual Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced that William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, is scheduled to speak at the Credit Suisse 18th Annual Healthcare Conference in Phoenix AZ. LabCorps presentation is planned for Friday, November 13, 2009 at 9:30 a.m. (Mountain Standard Time).

Sucampo Pharmaceuticals, Inc. Invites Investors to Listen to Webcast of Presentation at Conference
BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its presentation at the 2009 Annual Credit Suisse Health Care Conference will be webcast and may be accessed at www.sucampo.com.

Amylin Pharmaceuticals, Inc. to Present at the 18th Annual Healthcare Conference

SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the 18th Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals, will be providing a corporate overview.

<...

BioScrip to Present at 18th Annual Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced that it will present at the 18th Annual Credit Suisse Healthcare Conference to be held November 11-13, 2009 at the Arizona Biltmore Resort & Spa in Phoenix, Arizona.

King Pharmaceuticals??, Inc. to Present at Healthcare Conference
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast of its presentation scheduled for Thursday, November 12, 2009, at 9:00 am Mountain Standard Time (11:00 am Eastern Standard Time), at the Credit Suisse 2009 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona. The presentation may include a discussion of the Company...

Johnson & Johnson to Close Two Philadelphia Area Sites
Philly.com -- Johnson & Johnson said today that it was closing research & development facilities in Radnor and Chesterbrook and consolidating those operations at the company's Spring House site.

Danish Biotech Genmab A/S to Reorganize, to Sell U.S. Plant and Cut 300 Jobs

Discovery Laboratories Says to Look for Pipeline Funding

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer; Fails to Meet Secondary Endpoint of Overall Survival

Metabolex, Inc. Closes $8.6 Million Financing Round

Merck & Co., Inc. CEO "Actively Looking" for Biotech Deals

GenVec Inc. Cancer Drug Gets Orphan Status

Zyngenia Raises $10 Million in Series A Funding

Raptor Pharmaceutical Inc. Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference Proof-of-Concept Data at

NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. , today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

Mark...

Merck & Co., Inc. CEO Plans to Keep Schering-Plough Corporation Headquarters
Bloomberg -- Merck & Co. Chief Executive Officer Richard T. Clark said he plans to keep Schering-Plough Corp.s headquarters after completing the acquisition of the company.

Cardinal Health, Inc. Posts Net Loss Due to Costs of Spinoff

Biovail Corporation Profit Lower on Restructuring Charges

King Pharmaceuticals??, Inc. Reports Profit Fall

Pfizer Inc. Jury Said to Award $75 Million Prempro Verdict to Woman
Bloomberg -- Pfizer Inc. must pay about $75 million in punitive damages to an Illinois woman who developed cancer after taking one of the drugmakers menopause treatments, people familiar with a sealed verdict in the case said.

Astellas Pharma Inc. Cuts Outlook as Generic Competition Heats Up

Sunesis Pharmaceuticals, Inc.' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly...

New Merck & Co., Inc. Begins Operations Worldwide; Now No. 2 Drugmaker, Set for Future Buys

FDA Won't Accept Merck & Co., Inc.'s Application for New Drug

FDA Approves Nuvo Research Inc., Covidien's Pennsaid(R) Topical Solution

Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Phase 2 Data of Investigational Drug, Hematide, Suggest Its Ability to Restore Hemoglobin in Patients With Pure Red Cell Aplasia
PALO ALTO, Calif., & DEERFIELD, Ill.--(Business Wire)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research &Development Center, Inc., today announced data from a Phase 2 clinical trial ofHematide showing that Hematide increased hemoglobin and reduced or eliminatedthe need for blood transfusion in most patients with erythropoietin-induced purered cell aplasia (PRCA). The...

Breast Cancer Vaccine Tests German Merck KGaA's $1 Billion Strategy

Biovitrum AB and Swedish Orphan AB Combine to Form

Dong-A PharmTech Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development

SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective...

ERYtech Pharma Starts its Pivotal Clinical Trial for GRASPA(R) in Acute Lymphoblastic Leukaemia
LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. The endpoint combines safety and efficacy...

Abraxis BioScience, Inc. Release: ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the...

Affymax, Inc. and Takeda Global Research & Development Center, Inc. Announce Hematide(TM) Publication in the The New England Journal of Medicine
PALO ALTO, Calif., & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA). The data...

Data Demonstrating Aeolus Pharmaceuticals Inc.' AEOL 10150's Efficacy as a Broad Spectrum Pharmaceuticals, Inc. Countermeasure Against Radiological and Chemical Threats Presented at the
MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today the presentation of data at the GHSI Public Health Emergency Medical Countermeasures Workshop detailing the potential of AEOL 10150 as a broad spectrum medical countermeasure (MCM) to treat radiological and chemical threats. Data presented from studies sponsored by Aeolus, the National Institutes of Health...

Cellumen, Inc. Finds Increased Predictivity for Human DILI Through Rat Hepatocyte Panel
PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc., a discovery and early safety assessment company, today announced that its in vitro Rat Hepatocyte Early Safety Assessment Panel provides increased predictivity for human drug induced liver injury (DILI) equivalent to that of a recently published panel comprised of human hepatocytes. The implications of this study have a significant impact on cost and throughput...

Alnylam Pharmaceuticals Presents New Pre-Clinical Data on RNAi Therapeutics at Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi. In...

Complete Genomics, Inc. Publishes in Science on Low-Cost Sequencing of Three Human Genomes Using Its Proprietary Sequencing Platform
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays...

Micromet Buys Out MedImmune, LLC's Remaining Rights to Blinatumomab
BETHESDA, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune's rights to blinatumomab in North America, and to terminate the collaboration agreement signed in...

Elite Pharmaceuticals, Inc. Announces Second Closing of Strategic Alliance Agreement With
NORTHVALE, N.J., Nov. 5, 2009 (GLOBE NEWSWIRE) -- On October 30, 2009, Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) completed the second closing of the Strategic Alliance Agreement (the "Alliance") with Epic Pharma, LLC and Epic Investments, LLC, a wholly-owned subsidiary of Epic Pharma, LLC (collectively "Epic") pursuant to the terms in the Alliance entered into on March 18, 2009 and previously...

BioSpace.com Featured News

 

Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript

Halozyme Therapeutics, Inc. (HALO)

Q3 2009 Earnings Call Transcript

November 6, 2009 11:00 am ET

Complete Story »

Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript

Momenta Pharmaceuticals, Inc. (MNTA)

Q3 2009 Earnings Call Transcript

November 5, 2008, 10:00 am ET

Complete Story »

Myriad's Not Doing Much
Trader Mark submits:

We restarted a position in Myriad Genetics (MYGN) as a long term "growth at good value" play about 6 weeks ago, despite a horrid technical condition on the chart. Since then the stock has just sort of hung around and done nothing, trading in a very tight range. I was hoping this quarter's earnings report would provide some "oomph" but it appears we have nothing. No need to wait around at this point as the chart looks no better than it did 6 weeks ago, and now our catalyst to change that condition has come and gone. At this moment, the stock is simply in a slow downturn and is a better catch for the bears than for bulls.

I am selling our 1% exposure in the $24.40s for about a 5% loss on the remaining batch we owned. We traded around this position in small pieces during the past month but any gains or losses were inconsequential.

Complete Story »

Emergent BioSolutions Inc. Q3 2009 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS)

Q3 2009 Earnings Call Transcript

November 5, 2009 5:00 pm ET

Complete Story »

Targacept, Inc. Q3 2009 Earnings Call Transcript

Targacept, Inc. (TRGT)

Q3 2009 Earnings Call Transcript

November 5, 2009 5:00 pm ET

Complete Story »

Nabi Biopharmaceuticals Q3 2009 Earnings Call Transcript

Nabi Biopharmaceuticals (NABI)

Q3 2009 Earnings Call

November 05, 2009; 04:30 pm ET

Complete Story »

Penwest Pharmaceuticals Co. Q3 2009 Earnings Call Transcript

Penwest Pharmaceuticals Co. (PPCO)

Q3 2009 Earnings Call

November 5, 2009 11:00 am ET

Complete Story »

Theragenics Corporation Q3 2009 Earnings Call Transcript

Theragenics Corporation (TGX)

Q3 2009 Earnings Call Transcript

November 5, 2009 11:00 am ET

Complete Story »

MiddleBrook Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript

MiddleBrook Pharmaceuticals, Inc. (MBRK)

Q3 2009 Earnings Call

November 5, 2009 9:00 am ET

Complete Story »

ArQule, Inc. Q3 2009 Earnings Call Transcript

ArQule, Inc. (ARQL)

Q3 2009 Earnings Call Transcript

November 5, 2009 9:00 am ET

Complete Story »

Repligen Corp. F2Q09 (Qtr. End 09/30/09) Earnings Call Transcript

Repligen Corp. (RGEN)

F2Q09 (Qtr. End 09/30/09) Earnings Call

November 05, 2009 10:00 a.m. ET

Complete Story »

What We Like About Cubist Pharma
Andrew Horowitz submits:

We are carefully entering portfolio positions in this environment. (Note: Portfolio positions vs. trading positions) A company that we like for its specialty product is Cubist Pharmaceuticals (CBST). It has made all of our screens recently, but we were reluctant to add it to portfolios as the very recent trends have been down, down, down. The official line from the company’s description page:

Cubist Pharmaceuticals, Inc. (Cubist), is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company’s products are used primarily in hospitals but also may be used in acute care settings including home-infusion and hospital outpatient clinics. Cubist has one marketed product, an intravenous (IV) antibiotic, CUBICIN (daptomycin for injection). CUBICIN is approved in the United States for the treatment of complicated skin and skin structure infections (cSSSI), caused by Staphylococcus aureus (S. aureus) and certain other Gram-positive bacteria, and for blood-stream infections (bacteremia), including right-sided infective endocarditis, caused by methicillin susceptible and methicillin resistant S. aureus (MSSA and MRSA).

Complete Story »

Hemispherx Biopharma Could Become a Nice Rebound Story
VFC submits:

Shares of Hemispherx Biopharma, Inc. (HEB) rebounded slightly on Wednesday morning after sliding down to near the one dollar mark on Tuesday after it was announced that the company would spend the next two months responding to FDA queries regarding the company's New Drug Application for Ampligen. Ampligen is up for approval as a treatment for Chronic Fatigue Syndrome.

While Ampligen draws the news for Hemispherx at this time, the company also has already received FDA approval for Alferon, an injection that treats a category of sexually transmitted diseases.

Complete Story »

Novartis Joins Global Interest in Vaccines with Increased China Investments
ChinaBio Today submits:

Novartis (NYSE: NVS) continued its mega-investments in China by announcing it will spend $250 million to expand its global technical center in Changshu, and it will also pay $125 million to buy a 85% stake in a privately held China vaccine company, Zhejiang Tianyuan. Tuesday, Novartis said it would spend $1 billion over the next five years to expand its R&D facility in Shanghai, one of the institutions around the world that comprise the Novartis Institutes for BioMedical Research (NIBR).

Located outside of Suzhou, the Changshu Technical R&D Center focuses on the process and analytical R&D of innovative drugs. The provenance of the center includes both the substance and the manufacturing of the drugs.

Complete Story »

A 130 / 30 Global Pharma Strategy
Mike Havrilla submits:

Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent expiration exposure over the next 2-3 years includes Pfizer (NYSE: PFE), GlaxoSmithKline (NYSE: GSK), Takeda Pharma (OTC: TKPHY.PK), Sanofi-Aventis (SNY), AstraZeneca (AZN), and Merck (MRK).

The HavRx Global Generic Drug Index is actively managed and tracks the performance of companies which meet any of the following three requirements:

Complete Story »

Luminex Corporation Q3 2009 Earnings Call Transcript

Luminex Corporation (LMNX)

Q3 2009 Earnings Call

November 04, 2009; 05:00 pm ET

Complete Story »

Sangamo Biosciences, Inc. Q3 2009 Earnings Call Transcript

Sangamo Biosciences, Inc. (SGMO)

Q3 2009 Earnings Call Transcript

November 4, 2009 5:00 pm ET

Complete Story »

Vical, Inc. Q3 2009 Earnings Call Transcript

Vical, Inc. (VICL)

Q3 2009 Earnings Call

November 4, 2009 12:00 pm ET

Complete Story »

Synta Pharmaceuticals Corp. Q3 2009 Earnings Call Transcript

Synta Pharmaceuticals Corp. (SNTA)

Q3 2009 Earnings Call

November 4, 2009 10:00 am ET

Complete Story »

Charles River Laboratories International Inc., Q3 2009 Earnings Call Transcript

Charles River Laboratories International Inc. (CRL)

Q3 2009 Earnings Call

November 4, 2009 8:30 am ET

Complete Story »

Biotech Sector and Stocks Analysis from Seeking Alpha
'Biotech' Tag RSS Syndication from SeekingAlpha.com

 

Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Early recognition of symptoms such as fatigue and nausea, which occur frequently before an acute HAE attack, can provide patients with up to 24 hours to initiate treatment before further onset of the attack.

Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. The results come from a self-reported survey of patients conducted in parallel with the ongoing, prospective, open label International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 2) for C1-INH concentrate. Of the patients surveyed, 98.3 percent reported satisfaction with the treatment, with 37 percent responding that without C1-INH they would have sought emergency treatment and 43 percent would have deferred any medical therapy.

SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today reported financial results for the three and nine months ended September 30, 2009.

Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
DURHAM, N.C., Nov. 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that a previously approved reverse split of its common stock will take effect at the start of trading on Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted basis. Oxygen Biotherapeutics, Inc. shares will trade under the new symbol OXBT. The stock also will have a new CUSIP number, 69207P 20 9, when the split becomes effective.

Watson to Present at Credit Suisse Healthcare Conference
MORRISTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, 2009 at 12:00 pm Eastern Standard Time.

Microbix Biosystems Re-files Annual Results With OSC
TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (the "Company") announces today that it has re-filed the Form 52-109F1 Certification of Annual Filings of William Gastle, the Chief Executive Officer and James Long, the Chief Financial Officer (the "Officer's Certificates") dated January 12, 2009 in connection with the annual audited financial statements for the year ended September 30, 2008.

Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on November 10th, 2009.

Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants
QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myriant's biobased Succinic Acid plants based on renewable feedstocks. The execution of this alliance marks an important milestone in Myriant's commercialization of biobased Succinic Acid and exemplifies Uhde's continued commitment to the renewable chemicals industry.

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA:

GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
SPRING VALLEY, Calif., Nov. 6 /PRNewswire/ -- Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.

Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant
NATICK, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The alleged conduct and product sales occurred prior to Boston Scientific's 2006 acquisition of Guidant.

Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009.

NeurogesX Reports Third Quarter 2009 Results
SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --

EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
RICHMOND, Va., Nov. 6 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2009.

The Quigley Corporation to Announce Third Quarter Results and Host Audio Web Cast
DOYLESTOWN, Pa., Nov. 6 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced it will issue its third quarter results at 8:30 AM (ET) on Thursday, November 12, 2009.

Biotechnology
Press Releases from PR Newswire about Biotechnology

 

Graceway buys Gilead drug rights

Tennessee-based Graceway Pharmaceuticals, a portfolio company of GTCR Golder Rauner, has acquired worldwide rights to a Gilead Sciences molecule. Financial details of the deal were not disclosed. Graceway gains the topical drug GS 9191, which Gilead studied for external genital warts in a recent Phase II study. Graceway is hoping that GS 9191 will be effective in other skin conditions characterized by excessive cellular proliferation.

"The transaction with Gilead today is similar to our previous transaction with Pfizer in that we have licensed important compounds, processes, and intellectual properties that we hope will lead to exciting products for the treatment of important dermatological conditions faced by patients," stated Jefferson J. Gregory, Chairman and CEO of Graceway.

- check out Graceway's release

Related Articles:
Gilead touts Phase III hypertension drug
Gilead inks $1.4B buyout deal for CV Therapeutics
Gilead doubles jobs, space to boost development

Light Sciences lines up $35M in credit, financing

Bellevue, WA-based Light Sciences Oncology has garnered itself a $23.3 million line of credit, in addition to another $11.8 million in warrants. This comes after the company raised $40 million in venture capital in June 2008.

LSO is developing a medical device/drug combination that could treat malignant tumors without killing healthy surrounding tissue. The procedure involves inserting a light-emitting diode into tumors along with talaporfin sodium, an inactive chemical. When the light is turned on, it activates the chemical and destroys the cancer cells. The company began a late-stage trial of the drug for liver cancer in 2006. Although results from that study have yet to be released, LSO has already begun other trials in children with neurofibromatosis and men with enlarged prostates.

- here's the report from Xconomy

Related Articles:
Light Sciences Oncology - Top 20 VC deals of 2008
LSO rounds up $40M in third venture round

Micromet takes back MedImmune's blinatumomab rights

Bethesda, MD-based Micromet has agreed to buy out MedImmune's North American rights to blinatumomab, a potential treatment for lymphoma and leukemia.

As a result of the buyout, Micromet now controls global rights to develop and commercialize blinatumomab and any other BiTE antibodies for hematological cancers. The companies inked the blinatumomab agreement in 2003 and planned to create up to six novel drug candidates using Micromet's proprietary BiTE product platform.

"The advancement of blinatumomab in the clinic is the top priority for Micromet," company CEO Christian Itin says in a statement. "With complete control over global development and commercialization of blinatumomab, Micromet can develop an integrated clinical and regulatory strategy across multiple commercial territories, starting with the first pivotal study that we expect to initiate in 2010." 

- read Micromet's release

Related Articles:
Micromet inks $475M antibody deal with Sanofi
Micromet raising up to $80M to fund acquisitions, research
Micromet's blinatumomab shows promise in Phase I

Gloucester gains FDA approval of CTCL drug

Gloucester Pharmaceuticals said yesterday that the FDA has approved its lead drug Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL), a rare skin malignancy. In a trial of 167 patients, 40 percent of participants on the drug experienced tumor size reduction. Gloucester says the drug will be commercially available in January 2010. This marks Gloucester's first drug approval.

The company's investors were confident Gloucester's drug would gain approval; recently the developer raised $29 million in a fourth round of venture capital. Novo A/S led, Apple Tree Partners, ProQuest Investments, Prospect Venture Partners and Rho Ventures all participated.

"The approval of ISTODAX is a tremendous accomplishment for Gloucester Pharmaceuticals and for the patients we serve," said Alan Colowick, Gloucester's CEO. "This milestone is also an important step in the continued clinical development path for ISTODAX in oncology. We look forward to presenting data from our registration study of ISTODAX in peripheral T-cell lymphoma in 2010 and continuing further investigation in additional hematologic indications and solid tumors."

- check out Gloucester's release
- read the Xconomy story

Related Articles:
Bracing for FDA review, Gloucester bags $29M round
Gloucester Pharmaceuticals - Top 20 VC deals of 2008

Sequencing cost slides to $4,400 at Complete Genomics

Complete Genomics reported yesterday that it has successfully chipped away at the cost of sequencing a genome. Six years ago the cost was $300 million, a million smackers in 2007 and $60,000 last year. Now the company says its researchers completed the task at a cost of about $4,400 for the reagents needed to sequence three genomes.

Complete Genomics boasted last year that it had targeted a $5,000 price tag on sequencing, bringing the price down to the point where drug researchers could affordably include a genomics initiative to better understand disease triggers and the patient populations most likely to respond to new therapies. Ultimately Mountain View, CA-based Complete Genomics and competitors like Pacific Biosciences want to drive the cost down to less than $1,000, hoping to crack open a market in mainstream medicine where patients can afford to use it to analyze their risk of disease and better calculate which meds would be most effective for their condition.

For Complete Genomics, the drive to economize centers on the use of 200 nanometer DNA balls that assemble into ultra-dense arrays, speeding the analysis of the DNA and holding back on the reagent costs.

"For the first time this will enable large numbers of patients to be sequenced to get to the bottom of thousands of genetically controlled diseases," says Radoje Dramanac, Complete Genomics' chief scientist and the lead author of a paper in Science.

- here's the Complete Genomics' release
- read the piece from ScienceNOW

Related Articles:
Complete Genomics slashes the cost of genomic sequencing
Complete Genomics bags $45M round for sequencing
Complete Genomics plots $5,000 DNA scanning
Start-up to offer genome sequencing at bargain rate

Abraxis expands in Phoenix

Los Angeles-based Abraxis BioScience is expanding its Phoenix manufacturing facility, creating 200 new jobs in the area. "When all is said and done, this will be a $100 million investment," said Dr. Patrick Soon-Shiong, chairman of Abraxis. The company drug, Abraxane, has been approved in the U.S. and 38 other countries for breast cancer; it's currently in Phase III clinical trials for pancreatic, melanoma and lung cancer. Report

GenVec wins $22M vax development contract

GenVec is on a roll. A day after winning an orphan drug designation for its pancreatic cancer therapy TNFerade, the developer inked a $22 million development deal with Science Applications International to develop new HIV and flu vaccines. The contract is worth $22 million if all options are exercised and GenVec gets about $2.6 million over the next year. "Given the heightened concerns about influenza, this contract is timely and we look forward to applying our novel technology to the problem," says CEO Paul Fischer. "In particular we are looking forward to developing a universal flu vaccine, which has the potential to protect against seasonal and pandemic outbreaks." GenVec release

Genmab axing 300 as it shifts development work to vendors

Look for a spike in outsourcing at Genmab. The Danish antibody developer says it is reorganizing the company and turning to vendors to do more clinical development work after it axes 300 staff jobs and sells its U.S. manufacturing business.

"The workload for Genmab's development employees, in particular, has decreased and is expected to remain low as partners take on increasing responsibility for upcoming studies," the company said. "Genmab will adopt a more flexible model based on contracts with vendors to address varying demand for clinical development work going forward."

"It is vital that we refocus our energies on what Genmab is best at and what the pharmaceutical industry needs most - innovation," said Lisa N. Drakeman, Ph.D., the CEO of Genmab.  "The challenging demands on our industry require Genmab to take a hard look at our organization and continue to prioritize spending

Just last month the FDA approved Genmab's Arzerra, a leukemia drug partnered with GlaxoSmithKline. Glaxo says that it's confident that GenMab's restructuring won't affect their co-development work.

- read Genmab's release
- here's the story from Dow Jones

Related Articles:
Genmab wins $23M on blockbuster cancer approval
Genmab tanks on disappointing cancer data
GSK, Genmab touts Phase III RA drug data
Genmab shares slide on FDA delay

Nuvo, partner win FDA approval

The FDA has approved a new osteoarthritis therapy developed by Covidien and Nuvo Research. The non-steroidal anti-inflammatory Pennsaid will be marketed for osteoarthritis symptoms in the knee. Nuvo owns the IP on the product and Covidien will handle commercialization in the U.S. They're looking to launch in the first half of the year. Story

BioCryst reaps $22.5M windfall on IV peramivir order

Just days after federal regulators rushed through an emergency approval for the use of BioCryst's IV flu drug peramivir, the Alabama biotech says that it's shipped 10,000 courses of the treatment, reaping a windfall sale of $22.5 million. And the news helped buoy BioCryst's share price this morning.

The federal contract gives the government the right to buy another 30,000 courses, says TheStreet, noting that the company is charging the government $2,250 per course--at the high end of expectations. Just in case it's needed, BioCryst is making 120,000 more courses of the IV form of the drug, which is used for people who have been hospitalized with the flu. BioCryst CEO Jon Stonehouse says the company can make even more if needed.

"BioCryst has been in contact with a number of governments around the world that are assessing i.v. peramivir for critically ill influenza patients," says Stonehouse.

- check out the press release
- here's the report from Adam Feuerstein at TheStreet

Related Articles:
BioCryst outlines Phase III plans for peramivir
BioCryst hypes international pacts for peramivir
BioCryst reports positive late-stage flu data for peramivir
BioCryst cuts staff in lead-up to trial results
BioCryst trial scuttled by short needles, fat arms

FierceBiotech
Front Page News Posts

 

 

Search Powered By Google

   

Job & Career Search

                    job title, keywords, company, location

ADVERTISEMENT

Advertisement

Investing Jobs

Finance Jobs

Advertisement

MARKET INDICATORS

 

Stock Markets Overview
Volume Leaders
Percent Advances
Percent Declines
Daily 52 Week Highs
Daily 52 Week Lows
Market Indices
S&P 500
NASDAQ 100
Exchange Traded Funds - ETF Watch
FOREX FX Exchange Rates
Futures Prices by Exchange
Futures Prices by Type
US Morning Call Commentary

Stock Market News, Indicators, Market and Industry Articles Source. Find out what is happening in the Stock Markets. Visit iHaveNet.com for the latest Stock Market News by Sector and Industry. Your Single Source to Stock Market, Economic, Business and Industry News Articles.

ADVERTISEMENT

Job & Career Search

                    job title, keywords, company, location

Search Powered By Google

   

Advertisement